HALO vs. ICLR: Halozyme Therapeutics vs. ICON Stock Comparison

November 11, 2026

How do Halozyme Therapeutics (HALO) and ICON (ICLR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Halozyme Therapeutics (HALO) and ICON (ICLR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but HALO is classified in Biotechnology while ICLR is classified in Life Sciences Tools & Services.

Company profile comparison for Halozyme Therapeutics (HALO) and ICON (ICLR)
Profile Item	HALO	ICLR
Name	Halozyme Therapeutics Inc.	ICON plc
Country/Region	United States	Ireland
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Biotechnology	Life Sciences Tools & Services
GICS Sub-Industry	Biotechnology	Life Sciences Tools & Services
Market Capitalization	11.81 billion USD	15.34 billion USD
Currency	USD	USD
Exchange	Nasdaq	Nasdaq
Listing Date	March 16, 2004	May 15, 1998
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

HALO

ICLR

GSPC

Halozyme Therapeutics (HALO) vs. ICON (ICLR), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Halozyme Therapeutics (HALO) and ICON (ICLR). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Halozyme Therapeutics (HALO) and ICON (ICLR). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Halozyme Therapeutics (HALO) and ICON (ICLR)
Metric	HALO	ICLR
Total Return (1Y)	50.94%	30.55%
Total Return (3Y, Annualized)	41.08%	-6.05%
Total Return (5Y, Annualized)	21.68%	-5.40%

Risk Profile

Drawdown History

HALO

ICLR

GSPC

Halozyme Therapeutics (HALO) vs. ICON (ICLR), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Halozyme Therapeutics (HALO) and ICON (ICLR). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Halozyme Therapeutics (HALO) and ICON (ICLR)
Metric	HALO	ICLR
Volatility (1Y, Annualized)	41.19%	68.62%
Beta (5Y)	0.96	1.17
Max Drawdown (5Y)	-49.06%	-76.87%
Avg. Volume (3M)	2.29M	943.50K

Risk-Adjusted Performance

Risk-Return Positioning

HALO and ICLR are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Halozyme Therapeutics (HALO) and ICON (ICLR)
Metric	HALO	ICLR
Sharpe Ratio (1Y)	1.13	0.38
Sortino Ratio (1Y)	1.78	0.52

Profitability

ROE (TTM)

Halozyme Therapeutics (HALO) at 216.38% clears its industry range for ROE, a sharper capital-efficiency signal than ICON (ICLR) at 4.70%, which is closer to a typical peer reading.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

216.38%

HALO: 216.38%
Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.70%

Max: 109.18%
Q3: 6.23%
ICLR: 4.70%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

Halozyme Therapeutics (HALO) vs. ICON (ICLR): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Halozyme Therapeutics (HALO) at 26.93% keeps the most of each sales dollar — above its industry’s net margin range — and ICON (ICLR) at 5.26% also retains a top-quartile share.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.93%

HALO: 26.93%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

5.26%

Max: 18.05%
ICLR: 5.26%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Halozyme Therapeutics (HALO) vs. ICON (ICLR): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Halozyme Therapeutics (HALO) at 59.84% operates in the top operating margin quartile, ahead of ICON (ICLR) at 10.73%, which runs around its industry’s norm.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

59.84%

Max: 83.12%
HALO: 59.84%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.73%

Max: 83.12%
Q3: 14.77%
ICLR: 10.73%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Halozyme Therapeutics (HALO) vs. ICON (ICLR): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Halozyme Therapeutics (HALO) and ICON (ICLR)
Metric	HALO	ICLR
ROE (TTM)	216.38%	4.70%
ROA (TTM)	22.42%	0.85%
Net Margin (TTM)	26.93%	5.26%
Operating Margin (TTM)	59.84%	10.73%
Gross Margin (TTM)	77.74%	23.44%

Growth

Revenue Growth

Both Halozyme Therapeutics (HALO) at 37.55% and ICON (ICLR) at 0.76% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Halozyme Therapeutics (HALO) vs. ICON (ICLR): A comparison of their Revenue Growth across different time periods.

EPS Growth

Halozyme Therapeutics (HALO) at -25.36% is around its peer norm for EPS growth, while ICON (ICLR) at -71.56% drops into the bottom quartile, signaling weaker earnings momentum.

Halozyme Therapeutics (HALO) vs. ICON (ICLR): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Halozyme Therapeutics (HALO) and ICON (ICLR)
Metric	HALO	ICLR
Revenue Growth (YoY)	37.55%	0.76%
Revenue Growth (3Y CAGR)	28.38%	2.15%
EPS Growth (YoY)	-25.36%	-71.56%
EPS Growth (3Y CAGR)	21.14%	-23.82%

Financial Strength

Current Ratio (MRQ)

Halozyme Therapeutics (HALO) at 3.88 keeps current ratio within its industry’s typical mid-range, while ICON (ICLR) at 1.32 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ICLR.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.88

Max: 25.13
Q3: 12.13
Median: 5.52
HALO: 3.88
Q1: 2.47
Min: 0.10

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.32

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ICLR: 1.32
Min: 0.10

Halozyme Therapeutics (HALO) vs. ICON (ICLR): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: ICON (ICLR) carries debt-to-equity ratio of 0.38 against its industry range, while Halozyme Therapeutics (HALO) reports no figure this period.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
HALO: --

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.38

Max: 1.42
Q3: 0.65
ICLR: 0.38
Median: 0.15
Q1: 0.02
Min: 0.00

Halozyme Therapeutics (HALO) vs. ICON (ICLR): HALO does not report debt-to-equity ratio, so it has no value marker; ICLR is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Halozyme Therapeutics (HALO) and ICON (ICLR)
Metric	HALO	ICLR
Current Ratio (MRQ)	3.88	1.32
Debt / Equity (MRQ)	--	0.38
Net Debt / EBITDA	1.90	5.55

Dividends

Dividend Yield (TTM)

Neither Halozyme Therapeutics (HALO) nor ICON (ICLR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Halozyme Therapeutics (HALO) vs. ICON (ICLR): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Neither Halozyme Therapeutics (HALO) nor ICON (ICLR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

HALO: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

ICLR: 0.00%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Halozyme Therapeutics (HALO) vs. ICON (ICLR): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Halozyme Therapeutics (HALO) and ICON (ICLR)
Metric	HALO	ICLR
Dividend Yield (TTM)	0.00%	0.00%
Dividend Payout Ratio (TTM)	0.00%	0.00%

Valuation

P/E Ratio (TTM)

Halozyme Therapeutics (HALO) at 25.91 is near its industry’s usual P/E ratio, while ICON (ICLR) at 81.90 sits in the richer quartile — ICLR needs stronger growth or earnings quality to justify the premium.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.91

Max: 85.34
Q3: 43.46
Median: 26.69
HALO: 25.91
Q1: 13.30
Min: 0.07

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

81.90

Max: 85.34
ICLR: 81.90
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Halozyme Therapeutics (HALO) vs. ICON (ICLR): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

ICON (ICLR) at 1.86 sits in the cheaper P/S ratio quartile while Halozyme Therapeutics (HALO) at 6.55 prices around its industry’s middle — ICLR costs less per dollar of sales, though read it alongside growth and margins.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.55

Max: 58.18
Q3: 25.77
Median: 7.30
HALO: 6.55
Q1: 3.01
Min: 0.01

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.86

Max: 58.18
Q3: 25.77
Median: 7.30
Q1: 3.01
ICLR: 1.86
Min: 0.01

Halozyme Therapeutics (HALO) vs. ICON (ICLR): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Halozyme Therapeutics (HALO) reports a negative P/B ratio of -213.67, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile ICON (ICLR) reports 1.68, ranking against industry peers normally.

HALO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-213.67

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
HALO: -213.67

ICLR

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.68

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
ICLR: 1.68
Min: -5.59

Halozyme Therapeutics (HALO) vs. ICON (ICLR): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Halozyme Therapeutics (HALO) and ICON (ICLR)
Metric	HALO	ICLR
P/E Ratio (TTM)	25.91	81.90
P/S Ratio (TTM)	6.55	1.86
P/B Ratio (MRQ)	-213.67	1.68
Free Cash Flow Yield (TTM)	3.48%	3.51%